BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 3492531)

  • 1. Differences among immune complexes: association of C1q in SLE immune complexes with renal disease.
    Greisman SG; Redecha PB; Kimberly RP; Christian CL
    J Immunol; 1987 Feb; 138(3):739-45. PubMed ID: 3492531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating immune complexes in systemic lupus erythematosus: a reappraisal of the solid phase C1q radioimmunoassay.
    Woodroffe AJ; Nozza JM; Muller KD; McIntosh SL; Hale GM; Clarkson AR
    J Clin Lab Immunol; 1988 May; 26(1):5-7. PubMed ID: 3263507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mononuclear phagocyte system in SLE. II. A kinetic model of immune complex handling in systemic lupus erythematosus.
    Meryhew NL; Kimberly RP; Messner RP; Runquist OA
    J Immunol; 1986 Jul; 137(1):97-102. PubMed ID: 3486919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T; Fujita T; Kono I; Kabashima T; Yamane K; Tamura N; Kashiwagi H
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay, purification and further characterization of 7S C1q-precipitins (C1q-p) in hypocomplementemic vasculitis urticaria syndrome and systemic lupus erythematosus.
    Marder RJ; Potempa LA; Jones JV; Toriumi D; Schmid FR; Gewurz H
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():25-34. PubMed ID: 6375256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C1q-latex assay for immune complexes. Complexes that react with both C1q and monoclonal rheumatoid factor in lupus erythematosus and lung cancer.
    Medof ME
    J Lab Clin Med; 1982 May; 99(5):678-92. PubMed ID: 6978370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
    Wu CC; Bey RF; Loken KI
    Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune complex-like activity associated with abnormal serum lipoproteins in systemic erythematosus.
    Smith GW; Hannan SF; Scott PJ; Simpson IJ
    Clin Exp Immunol; 1982 Apr; 48(1):8-16. PubMed ID: 6979451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
    Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
    Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of C1q-bearing immune complexes by a monoclonal anti-C1q ELISA system.
    Antes U; Heinz HP; Loos M
    J Immunol Methods; 1987 Sep; 102(2):149-56. PubMed ID: 2443573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of immune complex levels--with special reference to C1q and the anti-antibody method].
    Kasukawa R
    Rinsho Byori; 1986 Oct; Spec No 69():35-44. PubMed ID: 3543438
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune complexes in systemic sclerosis; detection by C1q binding, K-cell inhibition and Raji cell radioimmunoassays.
    Hughes P; Cunningham J; Day M; Fitzgerald JC; French MA; Wright JK; Rowell NR
    J Clin Lab Immunol; 1983 Mar; 10(3):133-8. PubMed ID: 6601718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.
    Rossen RD; Crane MM; Morgan AC; Giannini EH; Giovanella BC; Stehlin JS; Twomey JJ; Hersh EM
    Cancer Res; 1983 Jan; 43(1):422-9. PubMed ID: 6600161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune complexes in Hodgkin's disease: isolation, immunochemical and physico-chemical analysis.
    Kilgallon W; Amlot PL; Williams BD
    Clin Exp Immunol; 1983 Aug; 53(2):308-18. PubMed ID: 6411401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of components of IC purified from human sera. I. Immune complexes purified from sera of patients with SLE.
    Maire MA; Barnet M; Carpentier N; Miescher PA; Lambert PH
    Clin Exp Immunol; 1983 Feb; 51(2):215-24. PubMed ID: 6839539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the C1q solid-phase binding assay for immune complexes. A clinical and laboratory study.
    Scullion M; Balint G; Whaley K
    J Clin Lab Immunol; 1979 Apr; 2(1):15-22. PubMed ID: 95801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of circulating immune complex assay in patients with systemic lupus erythematosus.
    Phi NC; Chien DK; Chinh DV; Péter G
    Acta Med Hung; 1989; 46(2-3):109-20. PubMed ID: 2812955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between circulating immune complexes and renal disease in New Zealand mice.
    Nakai Y; Yoshida H; Maruyama N; Shirai T; Hamashima Y
    Clin Exp Immunol; 1981 Feb; 43(2):240-5. PubMed ID: 6974065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.
    Baatrup G; Petersen I; Jensenius JC; Svehag SE
    Clin Exp Immunol; 1983 Nov; 54(2):439-47. PubMed ID: 6652967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.